- |||||||||| Review, Journal: Extranodal Rosai-Dorfman disease manifesting as Sj (Pubmed Central) - Apr 21, 2024
This is the first reported case of RDD presenting with SS in combination with panuveitis and HP. Although RDD is rarely diagnosed in young patients, interdisciplinary collaboration is essential to prevent a delayed diagnosis.
- |||||||||| Review, Journal: Acute calcareous corneal degeneration in a patient with chronic graft-versus-host disease. (Pubmed Central) - Apr 19, 2024
Calcareous corneal degeneration is a type of calcium deposition that can be secondary to chronic ocular inflammation or dry eye, but there are few cases reported of acute calcareous corneal degeneration and recurrent perforation in cGVHD. Abbreviations: GVHD = Chronic graft-versus-host disease, aGVHD = Acute graft-versus-host disease, cGVHD = Chronic graft-versus-host disease, KCS = Keratoconjunctivitis sicca, PKP = Penetrating keratoplasty, AMT = Amniotic membrane transplantation, PRGF = Plasma rich in growth factors, OD = Right eye, OS = Left eye.
- |||||||||| Review, Journal: The role of Epstein-Barr virus in autoimmune and autoinflammatory diseases. (Pubmed Central) - Apr 18, 2024
Research on therapeutic agents and vaccines for EBV has been stagnant for a long number of years until recent advances shed light on potential therapeutic targets. The implications of EBV in autoimmunity underscore the importance of developing targeted therapeutic strategies and, potentially, vaccines to mitigate the autoimmune burden associated with this ubiquitous virus.
- |||||||||| Trial completion, Trial completion date, Trial primary completion date: SAN-BB-01: At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions (clinicaltrials.gov) - Apr 17, 2024
P=N/A, N=17667, Completed, The implications of EBV in autoimmunity underscore the importance of developing targeted therapeutic strategies and, potentially, vaccines to mitigate the autoimmune burden associated with this ubiquitous virus. Recruiting --> Completed | Trial completion date: Dec 2040 --> Apr 2024 | Trial primary completion date: Aug 2025 --> Apr 2024
- |||||||||| venanprubart (LY3361237) / Eli Lilly
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's Syndrome (clinicaltrials.gov) - Apr 17, 2024 P2, N=0, Withdrawn, Recruiting --> Completed | Trial completion date: Dec 2040 --> Apr 2024 | Trial primary completion date: Aug 2025 --> Apr 2024 N=12 --> 0 | Trial completion date: Dec 2025 --> Jan 2028 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2025 --> Jan 2027
- |||||||||| venlafaxine / Generic mfg., pilocarpine / Generic mfg., alprazolam / Generic mfg.
Journal: A relatively rare traditional Chinese medicine pattern of primary Sj (Pubmed Central) - Apr 16, 2024 Tregs stimulation by IL-2LD is a promising therapeutic strategy and IL-2LD holds considerable promise for integration into combinatorial therapeutic approaches. This case report demonstrates that TCHM can effectively treat Primary Sj
- |||||||||| Journal: The immunoregulatory effects of total glucosides of paeony in autoimmune diseases. (Pubmed Central) - Apr 16, 2024
Moreover, TGP has been applied in the clinical treatment of various AIDs with satisfactory therapeutic outcomes and minor side effects. Thus, available studies have demonstrated that TGP and its bioactive constituents exhibit anti-inflammatory and immunomodulatory functions and may have extensive applications in the treatment of AIDs.
- |||||||||| Journal: Diagnostic significance of combined anti-extractable nuclear antigens antibody, anti-cardiolipin antibody and anti-?2-glycoprotein 1 in systemic lupus erythematosus patients. (Pubmed Central) - Apr 15, 2024
The combined use of age, sex, anti-ENA antibodies, ACA, and anti-?2 GPI antibodies yielded a sensitivity of 82.12% (80.41%-83.71%) and a specificity of 80.03% (76.77%-82.93%) for the diagnosis of SLE. The combination of age, sex, anti-ENA antibodies, ACA, and anti-?2 GPI antibodies shows high diagnostic value for SLE and holds potential for clinical application as an auxiliary diagnostic tool for SLE.
- |||||||||| sirolimus / Generic mfg.
Journal: Rapamycin can alleviate the submandibular gland pathology of Sj (Pubmed Central) - Apr 11, 2024 Maladaptive activation of autophagy and cGAS-STING signaling pathway are central contributors to the SG pathogenesis of pSS patient. Regulating autophagy by rapamycin may be a possible treatment for Sj
- |||||||||| Journal: CD4 T cell-secreted IFN-? in Sj (Pubmed Central) - Apr 8, 2024
Our findings indicate that CD4 T cell-secreted IFN-? in SS induces SGECs' ferroptosis and inhibits AQP5 expression.
- |||||||||| Journal: Sj (Pubmed Central) - Apr 7, 2024
This study does not provide evidence to support the assertion that SS has a conclusive impact on the risk of PD, which contradicts numerous existing observational reports. Further investigation is necessary to determine the possible mechanisms behind the associations observed in these observational studies.
- |||||||||| Journal: Mixed connective tissue disease and its management (Pubmed Central) - Apr 7, 2024
In this review, we describe the clinical features and the potential complications of this complex disease, often wrongly disregarded as benign. We will also emphasize the recommended follow-up exams and address treatment, which is currently lacking formal recommendations.
- |||||||||| azathioprine / Generic mfg., ursodeoxycholic acid / Generic mfg.
Journal: Unprecedented complexity of six coexisting autoimmune diseases: A case report. (Pubmed Central) - Apr 7, 2024 This patient presented with six concurrent distinct autoimmune disorders, categorizing this case as a type two multiple autoimmune syndrome. The identification of antisynthetase syndrome notably distinguishes this case.
- |||||||||| Journal, IO biomarker: Clinicopathological features of Sjogren's syndrome complicated with liver injury (Pubmed Central) - Apr 5, 2024
The inflammatory lesions of SS patients with autoimmune liver disease are the most serious, and the inflammatory lesions of SS patients with non-alcoholic fatty liver disease and non-specific inflammation are mild. Comprehensive analysis of liver histopathologic changes and laboratory findings is helpful for the diagnosis of SS complicated with different types of liver injury.
- |||||||||| Review, Journal: What can patients tell us in Sj (Pubmed Central) - Apr 4, 2024
The inclusion of PROMs is important for the success of such approaches. In this review we discuss the opportunities of using PROMs in understanding the pathogenesis of and therapeutic development for SS.
- |||||||||| Review, Journal: Evaluation of Event-Related Potentials in Somatic Diseases - Systematic Review. (Pubmed Central) - Apr 2, 2024
Event-related potential (ERP) methodology allows for monitoring neurocognitive processes and thus can provide a valuable window into these cognitive processes that are influenced, or brought about, by somatic disorders. The current review aims to present published studies on the relationships between somatic illness and brain function as assessed with ERP methodology, with the goal to discuss where this field of study is right now and suggest future directions.
- |||||||||| Preclinical, Journal: Regulation of STAT1 and STAT4 Expression by Growth Factor and Interferon Supplementation in Sj (Pubmed Central) - Apr 1, 2024
EGF/Interferon related pathways might be targeted to regulate STAT1 and STAT4 expression in salivary gland epithelial cells. Further investigation is required learn how to better target the Janus kinases/signal transducer and activator of transcription proteins (JAK/STAT) pathway-mediated inflammatory response in Sj
- |||||||||| New trial: UltraSj (clinicaltrials.gov) - Apr 1, 2024
P=N/A, N=800, Recruiting,
|